Holen Sie sich die Stockscreener-App
23.66
0.11%
0.025
Handel nachbörslich:
23.66
0.005
+0.02%
Schlusskurs vom Vortag:
$23.63
Offen:
$23.67
24-Stunden-Volumen:
1.39M
Relative Volume:
0.98
Marktkapitalisierung:
$2.93B
Einnahmen:
$376.07M
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-169.09
EPS:
-0.1399
Netto-Cashflow:
$-16.31M
1W Leistung:
+10.90%
1M Leistung:
-1.44%
6M Leistung:
+19.71%
1J Leistung:
+60.59%
1-Tages-Spanne:
$23.44
$24.24
1-Wochen-Bereich:
$21.84
$24.52
52-Wochen-Spanne:
$11.86
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
23.66 | 2.93B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - marketbeat.com
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - stocktitan.net
Responsive Playbooks and the ARQT Inflection - Stock Traders Daily
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - The Chronicle-Journal
Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - stocktitan.net
Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Arcutis executives join Needham virtual health conference April 14 - stocktitan.net
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat
Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada
Arcutis presents trial data on roflumilast cream for infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - stocktitan.net
Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
Fundamentals Check: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2026 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Stock Holdings Lessened by Suvretta Capital Management LLC - MarketBeat
Stock Recap: Can Arcutis Biotherapeutics Inc sustain earnings growth2026 WrapUp & Expert-Curated Trade Recommendations - baoquankhu1.vn
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis reports long-term data on eczema cream for young children - Investing.com Canada
Arcutis reports long-term data on eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Reports Positive Findings from Zo - GuruFocus
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - The Manila Times
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - Bitget
Year-long eczema study: Arcutis cream eased symptoms in young kids - Stock Titan
ARQT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline - TipRanks
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - AOL.com
American Century Companies Inc. Cuts Stock Position in Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):